EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

UKHCDO gene therapy taskforce: Guidance for implementation of haemophilia gene therapy into routine clinical practice for adults

Pratima Chowdary iD, Beatriz Duran, Paul Batty, Gillian Lowe, April Jones, Debra Pollard, Sara Boyce, Jayashree Motwani, Bahareh Amirloo, Kathryn Musgrave, David Hopper, Stephen Classey und 4 weitere

Haemophilia · 2025-01 · 31 (1) · 26-38

DOI: 10.1111/hae.15125 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Haemophilia, online erschienen am 20.11.2024. Verfasst von Pratima Chowdary und 15 weiteren Autor:innen. Beteiligte Einrichtung: Katharine Dormandy Haemophilia and Thrombosis Centre, Royal Free Hospital, London, UK. Hauptthemen laut MEDLINE: Genetic Therapy, Hemophilia A, Hemophilia B. Die Arbeit wurde bisher 22-mal zitiert (Crossref) und nennt 66 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Medical Research Council.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

2022 was a landmark year with two adeno‐associated viral vectors (AAVs) receiving conditional marketing authorization from EMA for the treatment of persons with severe haemophilia A and severe to moderately severe haemophilia B and a third in 2024. Gene therapy is a transformative, irreversible treatment with long‐lasting effects, necessitating development of new clinical pathways to ensure optimal outcomes.

Aim

To develop a consensus framework and service specification for delivery of AAV gene therapy for haemophilia in adults within the UK using the hub‐and‐spoke model proposed by the European Association of Haemophilia and Allied Disorders and the European Haemophilia Consortium.

Methods

The UK Haemophilia Centre Doctors Organisation (UKHCDO) set up a working party to develop expert consensus guidance, working with NHS England to ensure alignment with NHS England commissioning and the national service specification.

Results

These guidelines detail the patient pathway, counselling and governance requirements for the hub‐and‐spoke model. The national service specification requires the hub site to manage governance for AAV‐based gene therapy. Proposed regional and national multidisciplinary teams will harmonize clinical practices incorporating expertise from various specialities and professional groups. Key requirements identified include standardized documentation and multidisciplinary collaboration. Nationally agreed patient information and counselling checklists will streamline the informed consent process and facilitate data collection for long‐term safety and efficacy monitoring.

Conclusion

These guidelines provide a structured framework for the delivery of liver‐directed gene therapy. Whilst specific to the United Kingdom they provide a framework for the implementation of gene therapy in other countries for haemophilia and other monogenic disorders.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Genetic TherapyHemophilia AHemophilia BHumansAdultUnited KingdomDependovirus

Stichwörter der Autor:innen

UKHCDOclinical practice guidelinesgene therapyhaemophilia Ahaemophilia Bmultidisciplinarypatient pathway

Autor:innen und Institutionen

  • Katharine Dormandy Haemophilia and Thrombosis Centre, Royal Free Hospital, London, UK.
  • Department of Haematology, Cancer Institue, University College London, London, UK.
  • Pharmacy Department, Manchester University NHS Foundation Trust, Manchester, UK.
  • West Midlands Adult Comprehensive Care Haemophilia Centre, Queen Elizabeth Hospital, Birmingham, UK.
  • Haemophilia Centre, Royal Victoria Infirmary, The Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, UK.
  • University Hospital Southampton Haemophilia Comprehensive Care Centre, Southampton, UK.

ORCID-Profile: Pratima Chowdary, Annette Bowyer, Susan Shapiro

Förderung

  • Medical Research Council

Zitieren

APA

Chowdary, P., Duran, B., Batty, P., Lowe, G., Jones, A., Pollard, D., Boyce, S., Motwani, J., Amirloo, B., Musgrave, K., Hopper, D., Classey, S., Whitaker, S., Dunn, N., Bowyer, A., & Shapiro, S. (2025). UKHCDO gene therapy taskforce: Guidance for implementation of haemophilia gene therapy into routine clinical practice for adults. Haemophilia, 31(1), 26-38. https://doi.org/10.1111/hae.15125

Vancouver

Chowdary P, Duran B, Batty P, Lowe G, Jones A, Pollard D, et al. UKHCDO gene therapy taskforce: Guidance for implementation of haemophilia gene therapy into routine clinical practice for adults. Haemophilia. 2025;31(1):26-38. doi:10.1111/hae.15125

BibTeX
@article{Chowdary2025,
  author = {Chowdary, Pratima and Duran, Beatriz and Batty, Paul and Lowe, Gillian and Jones, April and Pollard, Debra and Boyce, Sara and Motwani, Jayashree and Amirloo, Bahareh and Musgrave, Kathryn and Hopper, David and Classey, Stephen and Whitaker, Sarah and Dunn, Nicola and Bowyer, Annette and Shapiro, Susan},
  title = {UKHCDO gene therapy taskforce: Guidance for implementation of haemophilia gene therapy into routine clinical practice for adults},
  journal = {Haemophilia},
  year = {2025},
  volume = {31},
  number = {1},
  pages = {26--38},
  doi = {10.1111/hae.15125}
}
Kostenlos starten →